Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies

In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including:

Practical differences among approved bispecific antibodies

Toxicity profiles of approved bispecific antibodies

When to refer patients for evaluation for immunotherapies

Considerations for sequencing bispecific antibodies in the relapsed/refractory setting

New findings with combination regimens with bispecific antibodies

Program faculty:

Doris K. Hansen, MD

Assistant Member, Blood and Marrow Transplant and Cellular Immunotherapy

H. Lee Moffitt Cancer…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.